GlobeNewsWire · IGF · November 2, 2026

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

Get the app for more

Explore stock news, insights and company research.